(Reuters) -Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease ...

Here are five things to know: Leqembi is meant only for people in the very early stages of Alzheimer’s disease. Alzheimer’s disease affects more than 6 million Americans.

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Additionally, Leqembi isn't cheap. The annual cost is $26,500. Medicare will cover 80% of that, but unless they have supplemental insurance or also are covered by Medicaid, many patients will have ...

LEQEMBI is the only FDA- approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. TOKYO and CAMBRIDGE, Mass., Jan ...

Leqembi, a drug that can help treat adult patients with Alzheimer’s, was given traditional approval by the FDA on Thursday. It was first approved in January for clinical trials.

The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Alzheimer's drug Leqembi – a treatment proven to slow the clinical aspects of the progressive disease – could soon be available at several major U.S. health care systems. The Food and Drug ...

A treatment for Alzheimer’s disease is on its way to many more patients across the U.S. The Food and Drug Administration on Thursday granted full approval to Leqembi, allowing Medicare enrollees ...

Leqembi is made by Japanese drugmaker Eisai and its partner Biogen, which is based in Cambridge, Massachusetts.. Medicare's decision to cover Leqembi, which came moments after the Food and Drug ...

The Food and Drug Administration’s decision to grant accelerated approval for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into ...